Takeda presents long-term data from phase 3 advance-cidp 3 clinical trial of hyqvia® in patients with chronic inflammatory demyelinating polyneuropathy (cidp) at pns annual meeting

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced data from the phase 3 advance-cidp 3 clinical trial, a long-term extension study evaluating the safety and efficacy of hyqvia® [immune globulin infusion 10% (human) with recombinant human hyaluronidase] in patients with chronic inflammatory demyelinating polyneuropathy (cidp). results showed favorable long-term safety and tolerability of hyqvia, and a low relapse rate, supporting its use as maintenance.
TAK Ratings Summary
TAK Quant Ranking